EP1439393A3 - Nachweisverfahren TIMP 1 verwendend für Kolonkrebs-Diagnose - Google Patents

Nachweisverfahren TIMP 1 verwendend für Kolonkrebs-Diagnose Download PDF

Info

Publication number
EP1439393A3
EP1439393A3 EP03257868A EP03257868A EP1439393A3 EP 1439393 A3 EP1439393 A3 EP 1439393A3 EP 03257868 A EP03257868 A EP 03257868A EP 03257868 A EP03257868 A EP 03257868A EP 1439393 A3 EP1439393 A3 EP 1439393A3
Authority
EP
European Patent Office
Prior art keywords
colorectal cancer
detecting
timp
colon cancer
detection methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03257868A
Other languages
English (en)
French (fr)
Other versions
EP1439393A2 (de
Inventor
Jon H. Astle
Lisa Allyn Boardman
Lawrence J. Bugart
Christopher C. Burgess
Theodore J. Catino
Poornima Dwivedi
Maryanne Huntress
Karen Anne Johnson
Marcia E. Lewis
Peter J. Maimonis
Susan H. Myerow
Sheryl Lynn Andrea Brown-Shimer
Arunthathi Thiagalingam
Stephen N. Thibodeau
Gary A. Molino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Bayer Healthcare LLC
Original Assignee
Mayo Foundation for Medical Education and Research
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Bayer Healthcare LLC filed Critical Mayo Foundation for Medical Education and Research
Publication of EP1439393A2 publication Critical patent/EP1439393A2/de
Publication of EP1439393A3 publication Critical patent/EP1439393A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP03257868A 2002-12-13 2003-12-15 Nachweisverfahren TIMP 1 verwendend für Kolonkrebs-Diagnose Withdrawn EP1439393A3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43355402P 2002-12-13 2002-12-13
US433554P 2002-12-13
US49139703P 2003-07-31 2003-07-31
US491397P 2003-07-31

Publications (2)

Publication Number Publication Date
EP1439393A2 EP1439393A2 (de) 2004-07-21
EP1439393A3 true EP1439393A3 (de) 2004-08-11

Family

ID=32600155

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03257868A Withdrawn EP1439393A3 (de) 2002-12-13 2003-12-15 Nachweisverfahren TIMP 1 verwendend für Kolonkrebs-Diagnose

Country Status (3)

Country Link
US (1) US20040157278A1 (de)
EP (1) EP1439393A3 (de)
JP (1) JP2004198419A (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060154245A1 (en) * 1999-04-09 2006-07-13 Rigshospitalet Method for detecting, screening and/or montoring a cancer in individual
ATE298890T1 (de) 1999-04-09 2005-07-15 Rigshospitalet Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
US7374886B2 (en) * 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
US7678889B2 (en) * 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005094863A1 (en) * 2004-03-30 2005-10-13 Den Kgl.Veterinær-Og Landbohøjskole Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and decting protease inhibitors
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP2006166732A (ja) * 2004-12-13 2006-06-29 Okayama Univ 消化器中の新生物の検出方法
ATE430936T1 (de) * 2004-12-23 2009-05-15 Hoffmann La Roche Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ES2323429T3 (es) * 2004-12-23 2009-07-15 F. Hoffmann-La Roche Ag Uso de la asc, como marcador para cancer colorrectal.
ES2717627T3 (es) 2005-07-29 2019-06-24 Siemens Healthcare Diagnostics Inc Métodos, kits, sistemas y bases de datos relacionados con enfermedades neoplásicas
CA2632327A1 (en) * 2005-12-22 2007-06-28 F. Hoffmann-La Roche Ag Use of a marker combination comprising osteopontin and carcinoembryonic antigen in the assessment of colorectal cancer
WO2007079218A2 (en) 2005-12-30 2007-07-12 Dyax Corp. Metalloproteinase binding proteins
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
DK2021794T3 (da) * 2006-05-19 2010-10-11 Hoffmann La Roche Anvendelse af protein S100A 12 som en markør for colorektal cancer
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919064B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919061B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
US9726670B2 (en) * 2007-07-19 2017-08-08 Biomerieux Method for the assay of liver fatty acid binding protein, ACE and CA 19-9 for the in vitro diagnosis of colorectal cancer
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919060B1 (fr) * 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
AU2008338421A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
EP2169078A1 (de) 2008-09-26 2010-03-31 Fundacion Gaiker Verfahren und Kits zur Diagnose und Abstufung von Kolorektalkrebs
JP4841656B2 (ja) * 2009-08-03 2011-12-21 株式会社江東微生物研究所 予後予測のための大腸癌組織の検査方法
IN2012DN03025A (de) 2009-09-09 2015-07-31 Ct Se Llc
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP6081911B2 (ja) 2010-06-14 2017-02-15 リケラ バイオメッド エスエーＬｙｋｅｒａ Ｂｉｏｍｅｄ Ｓａ Ｓ１００ａ４抗体およびその治療上の使用
DK2829881T3 (en) * 2010-07-14 2017-12-04 Vision Tech Bio Pty Ltd Colorectal cancer diagnostic
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
US20140199324A1 (en) * 2011-03-24 2014-07-17 Daniel T. Dransfield Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
CA2844822A1 (en) * 2011-08-31 2013-03-07 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of colorectal cancer
KR101877598B1 (ko) 2011-10-14 2018-07-11 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
WO2013092960A1 (en) 2011-12-22 2013-06-27 Fundacion Gaiker Methods and kits for the diagnosis of colorectal cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pirrolobenzodiazepine anti-CD22 antibody conjugates
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
ES2703151T3 (es) 2012-10-12 2019-03-07 Adc Therapeutics Sa Conjugados de anticuerpos de pirrolobenzodiazepinas
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
PT2839860T (pt) 2012-10-12 2019-07-29 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
EP2906250B1 (de) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
AU2014307080B2 (en) 2013-08-12 2018-06-07 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054983B1 (de) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepin-antikörper-konjugate
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (de) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepin-antikörper-konjugate
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6895254B2 (ja) 2013-12-16 2021-06-30 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CN107110865B (zh) * 2014-08-22 2020-01-10 雅培制药有限公司 用于结肠直肠癌的早期检测的方法
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (de) 2014-09-12 2019-11-20 Genentech, Inc. Anthracyclindisulfidzwischenprodukte, antikörper-wirkstoff-konjugate und verfahren
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
MA40575A (fr) 2014-09-17 2016-03-24 Genentech Inc Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
EP3236995A4 (de) 2014-12-23 2018-07-18 University of Maryland, Baltimore Muc1-köderpeptide zur behandlung und prävention von bakteriellen infektionen
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
EP3464280B1 (de) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol-antikörper-arzneimittelkonjugate und verfahren zur verwendung
EP3496763A1 (de) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepin-prodrugs und antikörperkonjugate davon
EP3522933B1 (de) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Verfahren zur herstellung von antikörperarzneimittelkonjugaten
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3612234B1 (de) 2017-04-20 2024-03-13 ADC Therapeutics SA Kombinationstherapie mit anti-axl-antikörper-arzneimittel-konjugat
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (ja) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
WO2020213344A1 (ja) * 2019-04-18 2020-10-22 学校法人慶應義塾 大腸癌の発癌リスクを検出する方法及びキット
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2023152133A1 (en) * 2022-02-08 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing colorectal cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012781A1 (en) * 1999-08-13 2001-02-22 Human Genome Sciences, Inc. 13 human colon and colon cancer associated proteins
WO2002086085A2 (en) * 2001-04-24 2002-10-31 Bayer Corporation Human timp-1 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374886B2 (en) * 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
US6397036B1 (en) * 1999-08-23 2002-05-28 Mindblazer, Inc. Systems, methods and computer program products for collaborative learning
US20030061330A1 (en) * 2000-09-29 2003-03-27 Frisco Lynn A. Web-based collaborative project and process management solution
WO2002044923A1 (en) * 2000-11-30 2002-06-06 Webtone Technologies, Inc. Web session collaboration
US6968346B2 (en) * 2001-04-23 2005-11-22 International Business Machines Corporation XML-based system and method for collaborative web-based design and verification of system-on-a-chip
US7039677B2 (en) * 2002-05-07 2006-05-02 International Business Machines Corporation Threaded text-based chat collaboration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012781A1 (en) * 1999-08-13 2001-02-22 Human Genome Sciences, Inc. 13 human colon and colon cancer associated proteins
WO2002086085A2 (en) * 2001-04-24 2002-10-31 Bayer Corporation Human timp-1 antibodies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HARADA K ET AL: "Human REG I gene is up-regulated in intrahepatic cholangiocarcinoma and its precursor lesions.", HEPATOLOGY (BALTIMORE, MD.) UNITED STATES MAY 2001, vol. 33, no. 5, May 2001 (2001-05-01), pages 1036 - 1042, XP002282254, ISSN: 0270-9139 *
HOLTON-ANDERSEN M N ET AL: "Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY. WINSTON, US, vol. 48, no. 8, August 2002 (2002-08-01), pages 1305 - 1313, XP002959679, ISSN: 0009-9147 *
OKUNO K ET AL: "Gene expression analysis in colorectal cancer using practical DNA array filter.", DISEASES OF THE COLON AND RECTUM. UNITED STATES FEB 2001, vol. 44, no. 2, February 2001 (2001-02-01), pages 295 - 299, XP009031427, ISSN: 0012-3706 *
PELLEGRINI P ET AL: "Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer.", CANCER IMMUNOLOGY, IMMUNOTHERAPY: CII. GERMANY SEP 2000, vol. 49, no. 7, September 2000 (2000-09-01), pages 388 - 394, XP002282255, ISSN: 0340-7004 *
XIAIQING LU ET AL: "IMMUNOLOGICAL QUANTIFATION OF LEVELS OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 IN HUMAN COLON CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 51, no. 23, PART 1, 1 December 1991 (1991-12-01), pages 6231 - 6235, XP000609477, ISSN: 0008-5472 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
US20040157278A1 (en) 2004-08-12
EP1439393A2 (de) 2004-07-21
JP2004198419A (ja) 2004-07-15

Similar Documents

Publication Publication Date Title
EP1439393A3 (de) Nachweisverfahren TIMP 1 verwendend für Kolonkrebs-Diagnose
WO2001018252A3 (en) Methods for disease detection
WO2004013357A3 (en) Nucleotide sequences specific to francisella tularensis and methods for the detection of francisella tularensis
ATE353975T1 (de) Diagnose von mit apoptose assoziierten erkrankungen mittels ermittlung des methylierungszustandes von apoptose-assozierten genen
WO2005045392A3 (en) Detection and identification of biopolymers using fluorescence quenching
WO2001042502A3 (en) Methods for disease detection
WO2004093644A3 (en) Methods and apparatus for genetic evaluation
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2006113466A3 (en) Methods and nucleic acids for analyses of cellular proliferative disorders
DE69535802D1 (de) Genetische veränderungen, die mit lungencarzinomen korrelieren
WO2006034879A3 (en) Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2007118704A3 (en) Methods and nucleic acids for the detection of colorectal cell proliferative disorders
WO2007070560A3 (en) Method for identification and monitoring of epigenetic modifications
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2009074328A3 (en) Methods and nucleic acids for analyses of lung carcinoma
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
WO2005001141A8 (en) Methods and nucleic acids for analyses of colorectal cell proliferative disorders
AU2003302964A1 (en) Compounds and methods for detection of carcinomas and their precursor lesions
WO2008008983A3 (en) Methods and nucleic acids for analyses of cellular proliferative disorders
WO2003078603A3 (en) Strong gene sets for glioma classification
WO2005001140A3 (en) Methods and nucleic acids for the analysis of colon cell proliferative disorders
WO2004109286A3 (en) Methods for detecting and treating cancer using podocalyxin and/or endoglycan
WO2006131677A3 (fr) Procede pour le diagnostic/pronostic du cancer du sein
WO2004084804A3 (en) Detection and monitoring of lung cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17P Request for examination filed

Effective date: 20041112

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MAYO FOUNDATION FOR MEDICALEDUCATION AND RESEARCH

Owner name: BAYER HEALTHCARE LLC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Owner name: SIEMENS HEALTHCARE DIAGNOSTICS INC.

17Q First examination report despatched

Effective date: 20080926

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090407